Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Xutao Guo, Yunxia Zhang, Haohao Lei, Yongqiang Wei, Xiaolei Wei, Qi Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 7249.

https://doi.org/10.1182/blood-2024-201948

Published: 2024

Journal Articles

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Yutian Yang, Minglang Zhan, Zhang Hanzhen, Xiaolei Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6244.

https://doi.org/10.1182/blood-2024-198161

Published: 2024

Journal Articles

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Zhang Hanzhen, Yongqiang Wei, Xiaolei Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 6456.

https://doi.org/10.1182/blood-2024-201377

Published: 2024

Journal Articles

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Yuqi Wang, Chen Huan, Zhang Hanzhen, Shanshan Zhang, Youhai Yuan, Ru Feng, Yongqiang Wei, Xiaolei Wei

Blood (2024) 144 (Supplement 1): 7031.

https://doi.org/10.1182/blood-2024-205810

Published: 2024

Journal Articles

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Xutao Guo, Xiaolei Wei, Yongqiang Wei, Qi Wei, Ning Su, Yunxia Zhang, Haohao Lei, Ru Feng

Blood (2024) 144 (Supplement 1): 6776.

https://doi.org/10.1182/blood-2024-207666

Published: 2024

Journal Articles

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

Xiaolei Wei, Xutao Guo, Qi Wei, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 3121.

https://doi.org/10.1182/blood-2024-204940

Published: 2024

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2024) 144 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2024-204915

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Mingyuan Sun, Junyuan Qi, Lugui Qiu, Jie Jin, Xin Li, Yongqiang Wei, Guimin Zhang, Xue Liu, Shaohong Yin

Blood (2023) 142 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2023-178948

Published: 2023

Journal Articles

Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

Yunxia Zhang, Haohao Lei, Xiaolei Wei, Yongqiang Wei, Ru Feng, Xutao Guo

Blood (2023) 142 (Supplement 1): 5792.

https://doi.org/10.1182/blood-2023-179874

Published: 2023

Journal Articles

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Xiaolei Wei, Xutao Guo, Qi Wei, Dan Xiong, Peng Zhang, Zewen Zhang, Yongqiang Wei, Ru Feng

Blood (2023) 142 (Supplement 1): 6223.

https://doi.org/10.1182/blood-2023-182496

Published: 2023

Journal Articles

Metabolic Tumor Volume from Baseline PET/CT Improves Stratification in the High IPI Risk Patients with Diffuse Large B‐Cell Lymphoma

Zhang Hanzhen, Xiaolei Wei, Wenlan Zhou, Zihan Xu, Junjie Chen, Yongqiang Wei, Hubing Wu, Ru Feng

Blood (2023) 142 (Supplement 1): 3131.

https://doi.org/10.1182/blood-2023-177938

Published: 2023

Journal Articles

The Prognostic Value of Dynamic Change of NK-Cell Counts in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Chen Huan, Zhongxin Zheng, Yongqiang Wei, Xutao Guo, Qi Wei, Ru Feng, Xiaolei Wei

Blood (2023) 142 (Supplement 1): 6262.

https://doi.org/10.1182/blood-2023-181412

Published: 2023

Journal Articles

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Blood (2022) 140 (Supplement 1): 9289–9291.

https://doi.org/10.1182/blood-2022-157311

Published: 2022

Journal Articles

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Blood (2022) 140 (Supplement 1): 3609–3611.

https://doi.org/10.1182/blood-2022-158675

Published: 2022

Journal Articles

Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice

Blood (2021) 138 (Supplement 1): 2718.

https://doi.org/10.1182/blood-2021-149058

Published: 2021

Journal Articles

The Efficacy of Plerixafor Plus Recombinant Human Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients with Lymphoma and Plasma Cell Diseases

Xutao Guo, Yongqiang Wei, Xiaolei Wei, Haiqing Zheng, Yunxia Zhang, Haohao Lei, Qi Wei, Qifa Liu, Ru Feng

Blood (2021) 138 (Supplement 1): 4851.

https://doi.org/10.1182/blood-2021-148487

Published: 2021

Journal Articles

CD30 Promotes Proliferation Via ERK 1/2 and p38 MAPK Signal Pathways in ABC-Diffuse Large B Cell Lymphoma

Weimin Huang, Xiaolei Wei, Yongqiang Wei, Ru Feng

Blood (2021) 138 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2021-146372

Published: 2021

Journal Articles

PKM2 Inhibition Enhances the Sensitivity of Doxorubicin in ABC Diffuse Large B-Cell Lymphoma Cells

Minglang Zhan, Xiaolei Wei, Weimin Huang, Yongqiang Wei, Ru Feng

Blood (2021) 138 (Supplement 1): 4336.

https://doi.org/10.1182/blood-2021-146371

Published: 2021

Journal Articles

CD44 Expression in Different Plasma Cell Diseases

Xueqin Ning, Xiaolei Wei, Bingyuan Chen, Zhen Li, Zhongxin Zheng, Zhengshan Yi, Ru Feng, Yongqiang Wei, Qifa Liu

Blood (2021) 138 (Supplement 1): 4754.

https://doi.org/10.1182/blood-2021-146780

Published: 2021

NARROW

The Effectiveness of Low-Dose Decitabine Following Infusion of Autologous Hematopoietic Stem Cells in Patients Experiencing Persistent Pancytopenia after CD19-CART

Inhibition of PKM2 Promotes Chemosensitivity of DOX in ABC-DLBCL Via Imbalance of Gsh/ROS and Inhibition of the NF-ΚB Pathway

Ultrasound Exhibited Superior Advantages over 18F-FDG PET/CT in Monitoring Follow-up of DLBCL

Comparative Efficacy of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Vs. Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRD) in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis

Optimizing Time-Limited Therapy in Unfit CLL/SLL Patients: Orelabrutinib, Bendamustine, and Obinutuzumab Combination (OBG) Regimen

Sintilimab, Rituximab and Lenalidomide (sR2) As First-Line Treatment in Elderly Patients with Diffuse Large B-Cell Lymphoma: A Single-Arm, Open-Label, Phase 2 Trial

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

A Phase 1 First-in-Human Monotherapy Study of F182112, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma

Curcumin Enhances Ibrutinib Induced Killing Effect Against TP53-Mutated Chronic Lymphocytic Leukemia Cells in Vitro

The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma

Metabolic Tumor Volume from Baseline PET/CT Improves Stratification in the High IPI Risk Patients with Diffuse Large B‐Cell Lymphoma

The Prognostic Value of Dynamic Change of NK-Cell Counts in Diffuse Large B-Cell Lymphoma Treated with R-CHOP

Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Ixazomib Based Maintenance Therapy for the Patients with Newly Diagnosed Multiple Myeloma in Real-World Practice

The Efficacy of Plerixafor Plus Recombinant Human Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients with Lymphoma and Plasma Cell Diseases

CD30 Promotes Proliferation Via ERK 1/2 and p38 MAPK Signal Pathways in ABC-Diffuse Large B Cell Lymphoma

PKM2 Inhibition Enhances the Sensitivity of Doxorubicin in ABC Diffuse Large B-Cell Lymphoma Cells

CD44 Expression in Different Plasma Cell Diseases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only